Every Form 4 that Ginkgo Bioworks Holdings Inc (DNA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNA filings page.
Ginkgo Bioworks Holdings, Inc. (DNA) reported insider equity activity by Chief Financial Officer Steven P. Coen. On August 21, 2026, 743 Restricted Stock Units vested and were converted into an equal number of Class A Common shares in two tranches of 587 and 156 RSUs. On August 24, 2026, Coen sold 330 shares of Class A Common Stock at $6.977 per share to cover tax withholding obligations related to vesting; the company states these sell-to-cover trades were not discretionary. The Rule 10b5-1 trading plan checkbox was not selected.
Canton Barry reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. reported that ten percent owner Barry Canton received four restricted stock unit awards on July 28, 2026, covering a total of 319,332 RSUs tied to Class A Common Stock. Two grants are held directly and two indirectly via his spouse, with portions vesting 75% on October 16, 2026 and 25% on January 21, 2027, and others vesting in equal quarterly installments over 12 quarters starting October 16, 2026.
Shetty Reshma P. reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. reported that President and Founder Reshma P. Shetty received four equity awards on July 28, 2026 in the form of restricted stock units convertible into Class A Common Stock. Directly and through her spouse, she was granted 39038, 127423, 35736 and 117135 RSUs. For awards with footnote F2, 75% vests on October 16, 2026 and 25% on January 21, 2027, while awards with footnote F3 vest in equal quarterly installments over 12 quarters starting October 16, 2026.
Kelly Jason R reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. granted Chief Executive Officer and founder Jason R. Kelly two awards of restricted stock units on July 28, 2026. One grant covers 74,258 RSUs vesting 75% on October 16, 2026 and 25% on January 21, 2027. The other grant covers 309,467 RSUs vesting in equal quarterly installments over 12 quarters starting October 16, 2026. Each RSU represents a contingent right to receive one share of Class A Common Stock.
Ginkgo Bioworks Holdings, Inc. Chief Financial Officer Steven P. Coen reported RSU vesting and related share movements. On July 16, 2026, 1,486 restricted stock units converted into Class A Common Stock. On July 17, 2026, he sold 752 shares at $7.903 per share to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement.
HENRY CHRISTIAN O reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. director Henry Christian O reported receiving a grant of 25,000 restricted stock units. Each RSU represents a contingent right to receive one share of Class A common stock. The award vests on the earlier of June 11, 2027 or the day before the next annual meeting, if he continues serving as a non-employee director. Following this grant, his reported RSU holdings from this award total 25,000 units.
Ginkgo Bioworks Holdings, Inc. reported that director Ross Fubini received a grant of 25,000 Restricted Stock Units on June 11, 2026. Each RSU represents a contingent right to one share of Class A common stock, with no cash exercise price.
The RSUs vest on the earlier of June 11, 2027 or the day immediately before the next annual meeting after the grant date, subject to Fubini continuing to serve as a non-employee director through the vesting date. Following this award, his directly held RSUs from this grant total 25,000 units.
Kosuri Sri reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. director Sri Kosuri received a grant of 25,000 restricted stock units on June 11, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of the company’s Class A common stock. The RSUs will vest on the earlier of June 11, 2027 or the day immediately before the next annual meeting after the grant date, provided Kosuri continues to serve as a non-employee director through that vesting date. This is a stock-based award, not an open-market share purchase or sale.
SLOAN HARRY reported acquisition or exercise transactions in this Form 4 filing.
Ginkgo Bioworks Holdings, Inc. director Harry Sloan received a grant of 25,000 restricted stock units on June 11, 2026. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest on the earlier of June 11, 2027 or the day before the next annual meeting, if he continues serving as a non-employee director.
Ginkgo Bioworks Holdings insider Steven P. Coen reported routine equity compensation activity involving restricted stock units and a related tax sale. On May 21, 2026, he exercised awards covering a total of 743 shares of Class A Common Stock at a conversion price of $0.00 per share, increasing his direct holdings.
On May 22, 2026, 307 shares of Class A Common Stock were sold at $8.334 per share to cover tax withholding obligations tied to the vesting of restricted stock and/or RSUs, as allowed under the company’s equity incentive plans. The footnotes state these "sell to cover" sales are not discretionary trades by the reporting person. After these transactions, Coen directly held 50,704 shares of Class A Common Stock.
Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported routine equity compensation activity involving restricted stock units. On April 16, 2026, he exercised RSUs to acquire a total of 743 shares of Class A Common Stock at a conversion price of $0.00 per share, reflecting vesting of previously granted awards.
On April 17, 2026, Coen sold 324 shares of Class A Common Stock at an average price of $7.952 per share. According to the disclosure, these shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock and RSUs and are not considered discretionary trades. After these transactions, he directly holds 50,268 shares of Class A Common Stock.
Ginkgo Bioworks Holdings, Inc. executive Steven P. Coen reported PSU vesting and related share activity. On April 10, 2026, he acquired a total of 73,921 shares of Class A Common Stock through the vesting and conversion of performance-based restricted stock units.
On April 13, 2026, he sold 33,171 shares at $6.414 per share solely to cover tax withholding obligations under a mandatory “sell to cover” mechanism, which the company’s equity plans permit and which is described as non-discretionary. After these transactions, he held 49,849 shares directly.
The PSUs were tied to cash flow reduction performance targets for the finance team and company-wide. One 45,755-PSU grant vested at 62% of its target, and a 67,991-PSU grant vested at 67%, as certified by the Compensation Committee.
Ginkgo Bioworks Holdings, Inc. major holder Canton Barry reported his spouse’s performance-based equity vesting and related tax sale. On April 9, 2026, 251,786 performance-based restricted stock units converted into an equal number of Class A shares at a $0.00 exercise price.
These PSUs came from a 375,800-unit grant tied to a company-wide cash flow reduction target for January 1, 2025 through December 31, 2025, with actual performance certified at 67% of target. On April 10, 2026, Barry’s spouse sold 124,727 Class A shares at $6.434 per share solely to cover tax withholding obligations under the issuer’s equity incentive plans, which the filing states were non-discretionary “sell to cover” transactions. After these transactions, 436,422 Class A shares were held indirectly through his spouse.
Ginkgo Bioworks Holdings director/officer Reshma P. Shetty exercised performance-based stock units and sold shares to cover taxes. On April 9, 2026, 251,786 performance-based restricted stock units vested and converted into Class A Common Stock based on a company-wide cash flow target achieved at 67% of goal.
These units came from a June 19, 2025 grant of 375,800 PSUs tied to cash flow performance for the period from January 1, 2025 to December 31, 2025. On April 10, 2026, 124,727 shares of Class A Common Stock were sold solely to satisfy tax withholding obligations under the company’s equity incentive plans through a required “sell to cover” transaction, which the disclosure states was not a discretionary trade. After these transactions, Shetty directly held 436,422 shares of Class A Common Stock.
Ginkgo Bioworks Holdings, Inc. director and officer Reshma P. Shetty, reporting indirect holdings "by spouse," disclosed PSU vesting and related share sales. On April 7–8, 2026, her spouse exercised 55,476 performance-based restricted stock units at $0.00 per unit into Class A Common Stock.
On April 8 and 9, 2026, a total of 26,271 Class A shares were sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations tied to the PSU vesting, which the footnotes state were not discretionary trades. After these transactions, the spouse’s indirect Class A Common Stock holdings were 338,568 shares.
Ginkgo Bioworks Holdings, Inc. 10% owner Barry Canton reported compensation-related stock activity tied to performance-based restricted stock units (PSUs). On April 7 and 8, 2026, he exercised 55,476 PSUs at $0.00 per unit, receiving the same number of Class A Common shares.
According to the disclosure, 26,271 Class A shares were then sold in open-market transactions at prices of $6.93 and $6.397 per share to cover tax withholding obligations upon PSU vesting. The filing notes these “sell to cover” trades are not discretionary. After these transactions, Canton directly held 338,568 Class A Common shares.
The PSUs stem from an 82,800-unit grant made on June 19, 2025, based on a company-wide cash flow reduction target for the period from January 1, 2025 to December 31, 2025. The total PSUs vested reflect performance at 67% of target, as certified by the board’s Compensation Committee.
Ginkgo Bioworks Holdings director and officer Jason R. Kelly reported PSU vesting and related share sales. On April 7 and 8, 2026, he exercised performance-based restricted stock units to receive a total of 425,898 shares of Class A Common Stock at a conversion price of $0.0000 per share.
Footnotes state that 206,782 of these shares were sold at prices of about $6.93 and $6.397 per share solely to cover tax withholding obligations in connection with the PSU vesting, under the company’s “sell to cover” provisions, and are not discretionary trades. After these transactions, he directly held 316,483 Class A shares.
The PSUs were part of a 635,670-unit grant dated June 19, 2025, tied to a company-wide cash flow reduction target for the period from January 1, 2025 to December 31, 2025, with actual performance certified at 67% and shares distributed on April 7 and 8, 2026.
Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported compensation-related equity activity involving restricted stock units (RSUs) and Class A Common Stock. On March 13, 2026, he exercised RSUs covering 1,486 shares, converting them into the same number of Class A shares at a per-share price of $0.0000. Each RSU represents a right to receive one share of Class A stock, and the RSUs vest over time according to pre-set schedules.
On March 16, 2026, Coen sold 708 shares of Class A Common Stock at an average price of $6.7350 per share. A footnote explains these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock and RSUs, and that such “sell to cover” transactions do not represent discretionary trades. Following these transactions, Coen directly owns 9,099 shares of Class A Common Stock.
Ginkgo Bioworks Holdings, Inc. Chief Financial Officer Steven P. Coen reported RSU vesting and a small share sale. On January 16, 2026, RSUs covering 587, 156, and 1,062 units were converted into the same number of Class A common shares at an exercise price of $0 per share, reflecting equity awards that had been vesting over time. After these conversions, he held 9,293 Class A shares directly. On January 20, 2026, he sold 972 Class A shares at $8.917 per share, leaving him with 8,321 shares. According to the footnotes, the sale was made to cover tax withholding obligations related to the vesting of restricted stock and RSUs and did not represent a discretionary trade.
Ginkgo Bioworks Holdings, Inc. reported insider equity transactions by a senior officer. On 12/12/2025, restricted stock units vested and were converted into 1,174 and 312 shares of Class A common stock, reflecting ongoing equity compensation. After these conversions, the officer directly held 8,224 Class A shares.
On 12/15/2025, 736 Class A shares were sold at $8.886 per share to satisfy tax withholding obligations tied to the vesting of restricted stock and restricted stock units. The company’s equity incentive plans allow these mandatory “sell to cover” transactions, which are described as non‑discretionary for the officer. Following the sale, the officer directly owned 7,488 Class A shares and continued to hold restricted stock units subject to multi‑year vesting schedules beginning May 1, 2024.
Ginkgo Bioworks (DNA) filed a Form 4 for its CFO showing routine equity activity tied to RSU vesting. On 10/16/2025, restricted stock units were converted to Class A shares via code M in three tranches: 1,174 shares, 312 shares, and 1,061 shares.
On 10/17/2025, the CFO sold 1,312 shares at $13.649 per share under code S to cover tax withholding related to these vestings, as permitted by the company’s equity plans. Following the transactions, the CFO directly beneficially owned 6,738 Class A shares.
Ginkgo Bioworks Holdings, Inc. (DNA) reporting person Coen Steven P., identified as an officer (Chief Financial Officer), sold 5,609 shares of Class A common stock on 10/01/2025 at a reported price of $15 per share under a sales plan intended to comply with Rule 10b5-1. Following the reported disposition, the filing shows the reporting person beneficially owns 5,503 shares, held directly. The Form 4 was signed by an attorney-in-fact, Karen Tepichin, on 10/03/2025. The filing includes an explicit remark that the sale was made pursuant to a Rule 10b5-1 plan and identifies the reporting person as the company’s Chief Financial Officer.